ライブラリ登録: Guest
Critical Reviews™ in Oncogenesis

年間 4 号発行

ISSN 印刷: 0893-9675

ISSN オンライン: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Therapeutic Targeting of BCR-ABL: Prognostic Markers of Response and Resistance Mechanism in Chronic Myeloid Leukaemia

巻 17, 発行 1, 2012, pp. 17-30
DOI: 10.1615/CritRevOncog.v17.i1.30
Get accessGet access

要約

Chronic myeloid leukemia (CML) is caused by the formation of the BCR-ABL fusion protein as a result of the t(9;22) chromosomal translocation. The elucidation of its molecular pathogenesis led to the identification of a therapeutic target and the subsequent synthesis and introduction of a small-molecule inhibitor for this target, imatinib. Because CML is the first disease successfully treated by targeted kinase inhibition, it served as a paradigm for discovery of disease mechanism and drug development in other diseases in which constitutive kinase expression plays a central role in pathogenesis. Despite the spectacular success of imatinib, not all CML patients derive great benefit from it. This review will cover some of the currently known prognostic markers of disease response and potential resistance mechanisms.

によって引用された
  1. Cleeland Charles S., Allen Jeff D., Roberts Samantha A., Brell Joanna M., Giralt Sergio A., Khakoo Aarif Y., Kirch Rebecca A., Kwitkowski Virginia E., Liao Zhongxing, Skillings Jamey, Reducing the toxicity of cancer therapy: recognizing needs, taking action, Nature Reviews Clinical Oncology, 9, 8, 2012. Crossref

  2. Breccia Massimo, Alimena Giuliana, Baccarani Michele, Bocchia Monica, Di Raimondo Francesco, Gambacorti-Passerini Carlo, Gozzini Antonella, Morra Enrica, Pane Fabrizio, Pregno Patrizia, Rege-Cambrin Giovanna, Rosti Gianantonio, Specchia Giorgina, Vigneri Paolo, Saglio Giuseppe, Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11–12, 2013, Critical Reviews in Oncology/Hematology, 90, 3, 2014. Crossref

  3. Giuliano Sandy, Pagès Gilles, Mechanisms of resistance to anti-angiogenesis therapies, Biochimie, 95, 6, 2013. Crossref

  4. Laurini Erik, Posocco Paola, Fermeglia Maurizio, Gibbons Don L., Quintás-Cardama Alfonso, Pricl Sabrina, Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments, Molecular Oncology, 7, 5, 2013. Crossref

  5. Breccia Massimo, Alimena Giuliana, Management Options for Refractory Chronic Myeloid Leukemia: Considerations for the Elderly, Drugs & Aging, 30, 7, 2013. Crossref

  6. Mortlock A., Foote K., Kettle J., Aquila B., Kinase Inhibitors in Cancer, in Reference Module in Chemistry, Molecular Sciences and Chemical Engineering, 2014. Crossref

  7. Penot Amélie, Preux Pierre-Marie, Le Guyader Sandra, Collignon Albert, Herry Aurélie, Dufour Vinciane, Monnereau Alain, Woronoff Anne-Sophie, Troussard Xavier, Pons Elisabeth, Bordessoule Dominique, Maynadié Marc, Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980–2009, Leukemia & Lymphoma, 56, 6, 2015. Crossref

  8. Breccia Massimo, Molica Matteo, Alimena Giuliana, How tyrosine kinase inhibitors impair metabolism and endocrine system function: A systematic updated review, Leukemia Research, 38, 12, 2014. Crossref

  9. Molica Matteo, Zacheo Irene, Diverio Daniela, Alimena Giuliana, Breccia Massimo, Long-term outcome of chronic myeloid leukaemia patients with p210 and p190 co-expression at baseline, British Journal of Haematology, 169, 1, 2015. Crossref

  10. Valent Peter, Sperr Wolfgang R, Sotlar Karl, Reiter Andreas, Akin Cem, Gotlib Jason, Horny Hans-Peter, Arock Michel, The serum tryptase test: an emerging robust biomarker in clinical hematology, Expert Review of Hematology, 7, 5, 2014. Crossref

  11. Ye Yuan-Xin, Zhou Juan, Zhou Yan-Hong, Zhou Yi, Song Xing-Bo, Wang Jun, Lin Li, Ying Bin-Wu, Lu Xiao-Jun, Clinical Significance of BCR-ABL Fusion Gene Subtypes in Chronic Myelogenous and Acute Lymphoblastic Leukemias, Asian Pacific Journal of Cancer Prevention, 15, 22, 2014. Crossref

  12. Breccia Massimo, Colafigli Gioia, Molica Matteo, Alimena Giuliana, Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia, Expert Opinion on Drug Safety, 15, 4, 2016. Crossref

  13. Breccia Massimo, Arboscello Eleonora, Bellodi Andrea, Colafigli Gioia, Molica Matteo, Bergamaschi Micaela, Massaro Fulvio, Quattrocchi Luisa, Sarocchi Matteo, Spallarossa Paolo, Alimena Giuliana, Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline, Critical Reviews in Oncology/Hematology, 107, 2016. Crossref

  14. Xia Chang-Qing, Zhang Pengcheng, Li Shiwu, Yuan Lihui, Xia Tina, Xie Chao, Clare-Salzler Michael J., Hribal Marta Letizia, C-Abl Inhibitor Imatinib Enhances Insulin Production by β Cells: C-Abl Negatively Regulates Insulin Production via Interfering with the Expression of NKx2.2 and GLUT-2, PLoS ONE, 9, 5, 2014. Crossref

  15. Hong David, Barata Pedro C., The Challenges of Implementing Multiarmed Early Phase Oncology Clinical Trials, in Novel Designs of Early Phase Trials for Cancer Therapeutics, 2018. Crossref

  16. Li Wei, Ji Min, Lu Fei, Pang Yihua, Dong Xin, Zhang Jingru, Li Peng, Ye Jingjing, Zang Shaolei, Ma Daoxin, Ji Chunyan, Novel AF1q/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia, Cell Death & Disease, 9, 9, 2018. Crossref

  17. Paolino Giovanni, Corsetti Paola, Moliterni Elisa, Corsetti Serena, Didona Dario, Albanesi Marcello, Mattozzi Carlo, Lido Paolo, Calvieri Stefano, Mast cells and cancer, Giornale Italiano di Dermatologia e Venereologia, 154, 6, 2019. Crossref

  18. Balakumaran Janatani, Birk Tanisha, Golemiec Breanne, Helmeczi Wryan, Inkaran Jeyanth, Kao Yun-ya, Leigh Jennifer, Saliba Sarah, Sharma Rishi, Spatafora Laura, Wright Kristin, Yao William, Hillis Christopher, Banfield Laura, Thabane Lehana, Athale Uma, Samaan M Constantine, Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol, BMJ Open, 9, 9, 2019. Crossref

  19. Tayanloo-Beik Akram, Sarvari Masoumeh, Payab Moloud, Gilany Kambiz, Alavi-Moghadam Sepideh, Gholami Mahdi, Goodarzi Parisa, Larijani Bagher, Arjmand Babak, OMICS insights into cancer histology; Metabolomics and proteomics approach, Clinical Biochemistry, 84, 2020. Crossref

  20. Zhang M, Luo Z, Liu H, Croce C M, Burke T R, Bottaro D P, Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist, Leukemia, 28, 4, 2014. Crossref

  21. Panagiotis Antoniadis, Florentina Alina Gheorghe, Madalina Ana Maria Nitu, Cezara Gabriela Nitu, Diana Roxana Constantinescu, Florentina Duica, New insights of liquid biopsy in ovarian cancer, Journal of Genetic Medicine and Gene Therapy, 5, 1, 2022. Crossref

Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集 価格及び購読のポリシー Begell House 連絡先 Language English 中文 Русский Português German French Spain